Comparison
CJC-1295 vs. SNAP-8
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Cosmetic
CAS no.
no data
868844-74-0
Molecular weight
3647.3 g/mol
1075.16 g/mol
Half-life
144 h
no data
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACAc-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Mechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
SNAP-8
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
Evidence base
Highest evidence
Human trial
Human trial
Studies
3
3
of which in humans
2
1
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
3
1